Health
This is to provide Latest HealthNews around the globe
-
Veterans deployed to Iraq and Afghanistan face higher risk of chronic respiratory conditions
In an evolving health landscape, emerging research continues to highlight concerns that could impact everyday wellbeing. Here’s the key update you should know about: U.S. Veterans who served in Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) face an increased risk of developing several chronic respiratory conditions, according to new research presented at the 2025 Annual Scientific Meeting of…
Read More » -
Is your employer cutting off your access to GLP-1 drugs? Tell us.
GLP-1 drugs have transformed the lives of many Massachusetts residents who have long struggled to lose weight. But the pricey medications are about to get harder for some people to afford. Starting on Jan. 1, several of the state’s biggest health insurers, including Blue Cross Blue Shield of Massachusetts and Point32Health, will no longer cover GLP-1s when they are prescribed…
Read More » -
The ‘hard, slow work’ of reducing overdose deaths is having an effect
Credit: Unsplash/CC0 Public Domain Illicit drug overdoses and the deaths they cause are trending down this year, despite spikes in a handful of states, according to a Stateline analysis of data from the federal Centers for Disease Control and Prevention. A handful of places with rising overdoses are responding to the problem with cooperation, they say, by sharing information about…
Read More » -
“Can You Use Word 'Dhoka'?” Delhi High Court Questions Patanjali Over Chyawanprash Ad In Dabur's… – Live Law
“Can You Use Word ‘Dhoka’?” Delhi High Court Questions Patanjali Over Chyawanprash Ad In Dabur’s… Live Law Delhi HC reserves order in Dabur’s suit against Patanjali over ‘dhokha’ chyawanprash ad The Indian Express Delhi HC issues notice to Patanjali to stop advertisement on plea by Dabur India ThePrint Delhi High Court Rebukes Patanjali for ‘Dhoka’ Chyawanprash Ad in Dabur Case scanx.trade ‘How Can You…
Read More » -
-Medtech_THAI_STUDIO_LAB_249_5668a625a9ad46978c78f22fdb7af040-620x480.jpg)
Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment
In an evolving health landscape, emerging research continues to highlight concerns that could impact everyday wellbeing. Here’s the key update you should know about: Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially improve their quality of life. Journal in which the study was…
Read More » -
New WHO report urges bold steps for equitable access to novel TB vaccines
A new WHO report launched today on the sidelines of the G20 Health Ministers Meeting in Limpopo, South Africa, calls for bold financing and access strategies to ensure novel tuberculosis (TB) vaccines reach adolescents and adults in high-burden countries. “New TB vaccines have the potential to save millions of lives faster and change the course of the epidemic,” said Dr…
Read More » -
Ivermectin seized from B.C. woman who says it heals cancer
Inspectors from Health Canada recently seized ivermectin from a Kelowna, B.C., wellness clinic owned by Svetlana Rilkoff, a former nurse who claims the drug heals cancer. Rilkoff shared video of the Oct. 30 seizure from Ezra Healing on social media, characterizing the incident as “stealing” by employees of “(death) Canada.” “They want to take away all my ivermectin that’s healing…
Read More » -
Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients
Credit: Pixabay/CC0 Public Domain Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States. A study appearing in Clinical Cancer Research found that adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with CLL to discontinue daily therapy and potentially improve their quality of life.…
Read More » -
Wegovy an instant hit among both patients and doctors – but with a warning
Wegovy is currently the only GLP-1 receptor agonist approved and available in New Zealand specifically for weight loss. Photo: AFP / Jens Kalaene More than 18,000 New Zealanders have been prescribed the weight-loss drug Wegovy in the past three months, according to provisional data from Health New Zealand. The injectable treatment, approved here from July, is available on prescription and…
Read More » -
How a few bat clades, not all, shape global spillover risk
In an evolving health landscape, emerging research continues to highlight concerns that could impact everyday wellbeing. Here’s the key update you should know about: A large-scale study reveals that only a few bat lineages harbor viruses with high epidemic potential, reshaping our understanding of zoonotic threats and calling for more targeted, clade-specific disease monitoring rather than a broad fear of…
Read More »
